论文部分内容阅读
SAVOR-TIMI 53临床试验结果的二次分析提示,将生物标志物[尤其是高敏肌钙蛋白T(hs-Tn T)和N末端B型钠尿肽原(NT-pro BNP)]数据与标准方案结合可改进稳定2型糖尿病患者的心血管危险分层。美国哈佛医院的Benjamin M Scirica博士认为,生物标志物特别是hs-Tn T和NT-pro BNP与其他许多我们常用的临床变量相比可更好地对稳定糖尿病患者进行危险分层。研究收
Secondary analysis of SAVOR-TIMI 53 clinical trial results suggested that biomarkers (especially hs-Tn T and NT-pro BNP) Combination of programs improves cardiovascular risk stratification in patients with stable type 2 diabetes. Dr. Benjamin M Scirica at Harvard Hospital in the United States believes that biomarkers, particularly hs-Tn T and NT-pro BNP, are better able to stratify risk stratification in stable diabetic patients compared to many of our commonly used clinical variables. Research income